$30 trln in additional investments required to achieve net zero in 8 hard-to-abate sectors
The Net Zero Industry Tracker 2024 estimates that $30 trillion in additional capital will be required across ...
Sanofi Egypt first in Africa to get approval for registering Dupixent
Sanofi Egypt is the first company in Africa to obtain approval for registering Dupixent as treatment for atopic dermatitis and severe uncontrolled asthma.
In a press release on Monday, Sanofi Egypt said Dupixent has been included on Egypt’s list of accredited medicine.
Patients at the age of 12 and more can use Dupixent.
Dr Ahmed Hegazy, the General Manager Egypt Sanofi Genzyme, said “this approval represents a new hope for patients suffering atopic dermatitis and severe uncontrolled asthma.”
He noted that atopic dermatitis patients are not only suffering from the disease, but also from its impact on their social and professional life.
He added that patients of sever uncontrolled asthma also suffer from difficulties in breathing that threat their lives so that they cannot survive a normal life. Patients cannot be committed to regularly attend classes, go to work or participate in social activities.
اترك تعليقا